Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aflibercept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Aflibercept. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2018-003298-90 Sponsor Protocol Number: OPT-302-1003 Start Date*: 2018-12-07
    Sponsor Name:Opthea Ltd
    Full Title: Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema
    Medical condition: Persistent central-involved diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-001764-29 Sponsor Protocol Number: VGFTe-ROP-1920 Start Date*: 2020-12-01
    Sponsor Name:Regeneron Pharmaceuticals. Inc.
    Full Title: Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) BG (Completed) BE (Completed) PT (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003695-23 Sponsor Protocol Number: 69HCL14-0201 Start Date*: 2015-07-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study
    Medical condition: inflammatory choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001063-82 Sponsor Protocol Number: KS301P105 Start Date*: 2021-01-14
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004648-12 Sponsor Protocol Number: CLS1003-301 Start Date*: 2018-01-15
    Sponsor Name:Clearside Biomedical, Inc.
    Full Title: SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
    Medical condition: Retinal Vein Occlusion
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PT (Completed) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000362-42 Sponsor Protocol Number: THR-687-002 Start Date*: 2021-10-06
    Sponsor Name:Oxurion NV
    Full Title: A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic ...
    Medical condition: Diabetic macular oedema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057915 Diabetic macular oedema LLT
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LT (Completed) LV (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004530-11 Sponsor Protocol Number: ALT-L9-03 Start Date*: 2022-04-21
    Sponsor Name:Altos Biologics Inc.
    Full Title: A Randomized, Phase 3, Double Masked, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of ALT L9 Versus Eylea® in Patients With Neovascular Age Related Macular Degeneration (ALT...
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LV (Completed) AT (Completed) ES (Ongoing) BG (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002003-25 Sponsor Protocol Number: Start Date*: 2016-06-02
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Phase II Trial of Aflibercept Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Metastatic Colorectal Cancer
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002567-26 Sponsor Protocol Number: ΗΕ6Α/13 Start Date*: 2014-03-04
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Single-arm phase II study of maintenance therapy with aflibercept after first-line treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003509-16 Sponsor Protocol Number: FLIBER Start Date*: 2018-03-02
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)
    Medical condition: Metastatic Colo-Rectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000329-11 Sponsor Protocol Number: Elderly Start Date*: 2018-05-02
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003428-35 Sponsor Protocol Number: KSI-CL-102 Start Date*: 2020-01-03
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Phase 2b/3, Prospective, Randomised, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in S...
    Medical condition: Neovascular (Wet) Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003515-10 Sponsor Protocol Number: BP41783 Start Date*: 2021-03-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABET...
    Medical condition: Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002168-34 Sponsor Protocol Number: FNB-OK-2013-01 Start Date*: 2014-12-09
    Sponsor Name:Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno
    Full Title: Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
    Medical condition: Retinal angiomatous proliferation secondary to wet age related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000272-26 Sponsor Protocol Number: HYKP1021 Start Date*: 2014-09-04
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (E...
    Medical condition: Macular Oedema due to Central Retinal Vein Occlusion (CRVO).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001837-10 Sponsor Protocol Number: PRODIGE25 Start Date*: 2016-09-27
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: PHASE II RANDOMIZED TRIAL EVALUATING AFLIBERCEPT ASSOCIATED WITH SCHEME LV5FU2 AS FIRST LINE TREATMENT OF NON-RESECTABLE METASTATIC COLORECTAL CANCERS
    Medical condition: first line of treatment for metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001062-11 Sponsor Protocol Number: KS301P104 Start Date*: 2021-01-20
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005263-33 Sponsor Protocol Number: AUG-201202-EyNeP Start Date*: 2015-04-29
    Sponsor Name:Medizinische Fakultät der Universität Bonn
    Full Title: Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum
    Medical condition: Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003133-42 Sponsor Protocol Number: 1672_2019 Start Date*: 2020-02-14
    Sponsor Name:Medical University of Vienna, Department of Ophthalmology and Optometry
    Full Title: Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study
    Medical condition: Nevoascular age related macular degneration (nAMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 07:56:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA